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Objective: Intraoperative imaging of intravascular thrombi is limited by the inability of visible light to penetrate
thick-walled vessels. Near-infrared (NIR) light has relatively high tissue penetration and low autofluorescence and scatter,
offering significant advantages. We hypothesized that the development of 700-nmNIR fluorophores for platelet labeling,
in conjunction with existing 800-nm NIR fluorophores, would permit simultaneous and separable quantitation of
intravascular thrombi and measurement of the antiplatelet effect of drugs.
Methods:We synthesized a series of lipophilic, cationic, polymethine indocyanine dyes (MHI-86, 94, 106, and 114) that
emit at approximately 700 nm. Platelet uptake was optimized in vitro and the bioactivity and blood half-life of labeled
platelets was characterized in vitro and in vivo. FeCl3-induced injury of the femoral arteries and intravascular thrombus
formation was performed in 35-kg Yorkshire pigs. A combination of 700-nm and 800-nm NIR fluorophore-labeled
platelets was used in conjunction with the fluorescence-assisted resection and exploration imaging system to image and
quantify the antiplatelet effect of cilostazol and acetylsalicylic acid.
Results:MHI-114was incorporated at nearly 4.1 106molecules per platelet without affectingplatelet function.When infused
into pigs, the signal-to-background ratio ofMHI-114-labeled platelets exhibited a bloodhalf-life of 16.42.2 (meanSEM;n
3) minute and generated a signal-to-background ratio of 2.5  0.5 (mean  SEM; n  3) at the site of thrombi. Using
dual-NIR-labeled platelet populations, cilostazol and acetylsalicylic acid were found to cause a reduction in platelet incorporation
into thrombi of 51 2% and 10 1% (mean SEM; n 3), respectively, relative to vehicle-only treated control thrombi.
Conclusions: New platelet-avid 700-nm NIR fluorophores permit simultaneous two-wavelength NIR fluorescence
imaging and quantitation of intravascular thrombi in intact vessels approaching the size of humans and can be used to
study the antiplatelet effect of drugs. (J Vasc Surg 2012;56:171-80.)
Clinical Relevance:Occult thrombus formation during surgery leads to significant morbidity and mortality. We describe
the synthesis of a novel family of 700-nm near-infrared fluorophores that concentrate into platelets and render them
highly fluorescent while maintaining bioactivity. Using these platelets and a near-infrared imaging system, we can detect
thrombi in thick-walled vessels intraoperatively with high signal-to-background ratio  2.5. The optical properties and
blood half-life of these 700-nm fluorophores complement a previously described 800-nm platelet-avid fluorophore and
enable the assessment of antiplatelet interventions intraoperatively.
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July 2012172 Ashitate et alnonoptical probes, optical imaging enables simultaneous
localization of multiple probes emitting at different wave-
lengths without the need for ionizing radiation. The use of
near-infrared (NIR; 700 nm-900 nm) fluorescence emis-
sion enables optical imaging of thick tissues. Our group has
previously demonstrated the use of a commercially available
800-nm platelet-avid NIR fluorophore for thrombus imag-
ing in large vessels of pig model systems.9
The enabling technology for our study is the fluores-
cence-assisted resection and exploration (FLARE) optical
imaging system, which provides simultaneous acquisition
of color video and two independent channels of invisible
NIR fluorescence, one centered at 700 nm and the other at
800 nm. The potential use of this imaging system is quan-
titative comparison of two cellular subpopulations within a
single location. This approach enables direct comparison of
a population that has been modified (eg, by a drug or
genetic manipulation) with a control population. For ex-
ample, a useful technique in assessing mechanisms of throm-
bus formation and testing antithrombotic compounds has
been the use of videomicroscopy for near-simultaneous imag-
ing to measure two platelet populations stained with different
visible fluorophores.10
In this study, we hypothesized that synthesis of 700-nm
platelet-avid NIR fluorophores would permit two indepen-
dent populations of platelets to be studied in large vessels
approaching the size of human vessels.
METHODS
Preparation of IR-786 orMHI-dye-labeled washed
platelets. For in vitro studies, washed human platelets were
prepared from fresh blood obtained from aspirin-free do-
nors and processed using differential centrifugation.4,11
For in vivo studies, autologous washed pig platelets were
isolated, as reported previously,9 from the blood of anes-
thetized Yorkshire pigs. Briefly, platelet-rich plasma (PRP)
was prepared by centrifugation at 200  g for 20 minutes.
Platelets were then isolated from PRP by centrifugation at
1400  g for 10 minutes in the presence of 50-ng/mL
prostaglandin E1 and 10% (v/v) acid citrate/dextrose, pH
4.6, and resuspended at a concentration of 4  108
cells/mL in Tyrode’s-HEPES buffer. The perchlorate salt
of IR-786 (CAS #102185-03-5) was purchased from
Sigma-Aldrich (St Louis, Mo). The platelets isolated from
one pig were used only for that pig.
Quantification of NIR dye uptake into platelets.
Platelet counts were measured using the HEMAVET Multi-
species Hematology Analyzer (Drew Scientific, Oxford,
Conn). To determine which MHI (MHI-84, 96, 106, and
114) showed the highest uptake into platelets, 1-mL samples
ofwashed humanplatelets (approximately 4108 total) were
incubated for 0, 15, 30, 60, 90, or 120 minutes at room
temperature with 4 M of each MHI dye or 2-M IR-786
(n  3 for each dye). To determine the optimal loading
concentration, washed human platelets were incubated with
0.5, 1, 2, 4, or 8 M of the NIR fluorophore under study
(n 3 for each dye). eSpectral measurements. The optical properties of all
gents were measured in fetal bovine serum (FBS). The
uantum yield of contrast agents in FBS was calculated
sing indocyanine green in dimethyl sulfoxide (DMSO;
uantum yield 13%)12 as the calibration standard. For in
itro optical property measurements, online fiber-optic
R2000 absorbance (200-1100 nm) and USB2000FL
uorescence (350-1000 nm) spectrometers (OceanOptics,
unedin, Fla) were used. NIR excitation was provided by a
70-nm NIR laser diode light source (ElectroOptical
omponents, Santa Rosa, Calif) set to 8 mW and coupled
hrough a 300-M core diameter, 0.22-NA fiber (Fiber-
uide Industries, Stirling, NJ).
NIR fluorescence microscopy. NIR fluorescence mi-
roscopy was performed on a four-filter set Nikon Eclipse
E300 epifluorescence microscope as previously de-
cribed.13 The microscope was equipped with a 100-W
ercury light source, NIR-compatible optics, and an NIR-
ompatible 10 Plan Fluor objective lens and a 100 Plan
po oil immersion objective lens (Nikon, Melville, NY).
mages were acquired on an Orca-AG (Hamamatsu,
ridgewater, NJ). Image acquisition and analysis was per-
ormed using IPLab software (Scanalytics, Fairfax, Va). A
ustom filter set (Chroma Technology Corporation,
rattleboro, Vt) composed of a 750  25-nm excitation
lter, a 785-nm dichroic mirror, and an 810  20-nm
mission filter were used to detect IR-786. For MHI de-
ection, we used 650  22-nm and 710  25-nm excita-
ion and emission filters.
Platelet aggregation studies. Control and experi-
ental platelets labeled with MHI-114 or IR-786 were
esuspended at a density of 4  108 cells/mL in modified
yrode’s-HEPES buffer and stimulated with agonists in
iliconized glass tubes in an optical aggregometer (Chrono-
og, Havertown, Pa). Assays were performed at 37°C with
onstant stirring. Aggregation was monitored by measur-
ng the optical density of the platelet suspension.14
Animal studies. Sixteen female Yorkshire pigs
E. M. Parsons and Sons, Hadley, Mass) averaging 35.4
g were used under the supervision of an approved
nstitutional protocol. Because the SE of NIR fluores-
ence measurements was low, and we are mandated by
he institutional protocol to use the smallest number of
nimals needed to assess statistical significance, we used
hree pigs to meet the predefined statistical criteria.
onsequently, we used three pigs for each of the follow-
ng studies: blood half-life measurement of MHI-114
n  3) and IR-786 (n  3), signal-to-background ratio
SBR) measurement of MHI-114-labeled thrombi (n 
), and measurement of the antiplatelet effects of cilosta-
ol (CILO; n  3) and acetylsalicylic acid (ASA; n  3).
dditionally, one pig was used for in vivo microscopic
maging. All 16 pigs were induced with 4.4-mg/kg intra-
uscular Telazol, intubated, and maintained with 2% iso-
urane. Electrocardiogram, heart rate, oxygen saturation,
nd body temperatureweremonitored throughout the exper-
ment. A 14G central venous catheter was inserted into the
xternal jugular vein. After preparation, the indicated vessels
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Volume 56, Number 1 Ashitate et al 173Fig 1. Optical properties of near-infrared (NIR) fluorophores and their incorporation into platelets. A, Chemical
structures and optical properties of novel 700-nm NIR fluorophores (above dashed line) and commercially available
800-nm fluorophore IR-786 (below dashed line). B,NIR fluorophore incorporation into platelets as a function of time
at room temperature. Shown are mean SEM for three independent experiments. Statistical assessments of MHI-114
vs MHI-106, MHI-114 vs MHI-96, andMHI-114 vs MHI-84 (right) are shown. Statistical assessments of the various
incubation times ofMHI-114 at 30minutes vs 60 minutes, 60 minutes vs 120minutes, and 30minutes vs 120minutes
(top) are also shown. **P .01, and ***P .001, using a one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison test. C, Relationship between extracellular NIR fluorophore concentration and final uptake into
platelets for MHI-114 and IR-786. Shown are mean SEM for three independent experiments. Statistical assessments
of the various loading concentrations of MHI-114 at 2 M vs 4 M, 2 M vs 8 M, and 4 M vs 8 M are shown.
***P  .001, using a one-way ANOVA followed by Tukey’s multiple comparison test. FBS, Fetal bovine serum;
FLARE, fluorescence-assisted resection and exploration.
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July 2012174 Ashitate et alwere exposed using standard surgical techniques and samples
processed for hematoxylin and eosin (H&E) staining. CILO,
a phosphodiesterase 3A inhibitor, was purchased from Tocris
Bioscience (Ellisville, Mo). Acetylsalicylic acid (aspirin) was
purchased from Bayer Healthcare (Morristown, NJ).
Blood clearance of the NIR fluorescence signal.
Fig 2. Bioactivity and blood half-life of MHI-114-la
dimethyl sulfoxide (DMSO; vehicle control) or near-in
minutes at room temperature; right, 2 M IR-786 for 3
1 U/mL thrombin (top) or 2 g/mL collagen-related pr
are from four independent experiments.B,Blood half-life
MHI-114 (black squares) for 120 minutes or 2 M IR
measured after intravenous infusion into Yorkshire pigs.
indicated times were quantified using the fluorescence-assis
are mean SEM for three independent experiments. SBRWashed autologous pig platelets (3.9  1010) were qabeled with MHI-114 or IR-786 and infused through a
entral venous catheter inserted into the external jugular
ein (n  3 for each dye). Blood samples were obtained
t 2, 5, 10, 15, 30, 45, 60, 90, 120, and 180 minutes,
nd the PRP was analyzed. The fluorescence intensity
FI) of PRP was measured. The SBR was assessed by
platelets. A, Washed platelets incubated with either
d (NIR) fluorophores (left, 4 M MHI-114 for 120
utes at room temperature), then stimulated with either
(CRP) (bottom). Representative aggregometry tracings
9 1010 autologous washed platelets labeled with 4M
(white squares) for 30 minutes at room temperature,
let-rich plasma isolated from blood samples taken at the
section and exploration (FLARE) imaging system. Shown
al-to-background ratio.beled
frare
0 min
otein
of 1.
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Volume 56, Number 1 Ashitate et al 175clearance, the SBR was defined as the NIR fluorescence
intensity of the PRP at the indicated time divided by that
of the preinjection PRP.
Vessel injury models. Platelets (1.3-1.9 1010 total)
in Tyrode’s-HEPES were labeled with MHI-114 dye or
IR-786 and infused intravenously before induction of
thrombi using FeCl3. For induction of thrombus forma-
tion, a 0.5-  1-cm Whatman grade 413 filter paper was
saturated with a 50% solution of FeCl3 (Sigma-Aldrich) and
applied beneath the vessel. Parafilm (Pechiney, Chicago,
Ill) was used to protect the surrounding tissue from oxida-
tive injury induced by FeCl3. Thrombus formation was
then imaged continuously until the fluorescence signal was
stabilized.
Intraoperative NIR fluorescence imaging system
and quantitation. The dual-NIR channel FLARE imag-
ing system has been described in detail previously.15,16 In
this study, 670-nm excitation and 760-nm excitation flu-
Fig 3. Real-time detection of thrombus formation i
platelets. A, MHI-114-labeled autologous pig platele
femoral artery to FeCl3. Shown are color video (left),
pseudocolored (red) merge of the two (right). The fem
thrombus exposed and imaged. Arrows indicate locati
three independent femoral artery thrombi are shown.
FeCl3-induced femoral artery injury after infusion of
three independent experiments.ency rates used were 4.0 and 11.0 mW/cm2, respectively, vith white light (400-650 nm) at 40,000 lx. Color video
nd two independent channels (700 nm and 800 nm) of
IR fluorescence images were acquired simultaneously
ith custom software at rates up to 15 Hz over a 15-cm
iameter field of view. In the color-NIR merged images,
00-nm NIR fluorescence (MHI dyes) and 800-nm fluo-
escence (IR-786) were pseudocolored red and green, re-
pectively. The imaging system was positioned at a distance
f 18 inches from the surgical field. Regions of interest
ROI) of a defined shape and pixel number were drawn to
uantify the FI of intravascular thrombi. SBR was defined
s the FI of the ROI over the thrombus divided by that of
he same size and shape ROI over the vessel proximal to the
hrombus.
Statistical analysis. Results were presented as mean
EM. A one-way analysis of variance (ANOVA) followed
y Tukey’s multiple comparisons test were used to assess
he statistical differences between multiple groups. A P
act porcine femoral arteries using MHI-114-labeled
9  1010) were infused 20 minutes after exposure of
nm near-infrared (NIR) fluorescence (middle), and a
rtery was subsequently dissected (bottom row) and the
intravascular thrombus. Representative images from
uantitation of NIR fluorescence signal at the site of
-114-labeled platelets. Shown are mean  SEM forn int
ts (3.
700-
oral a
on of
B, Q
MHIalue of less than .05 was considered significant.
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July 2012176 Ashitate et alFig 4. Two-wavelength detection of thrombus following FeCl3-induced injury using IR-786-labeled and MHI-
114-labeled platelets. A, Platelets separately loaded with 4-M MHI-114 for 120 minutes at room temperature
or 2-M IR-786 for 30 minutes at room temperature and settled onto glass slides. Shown are phase contrast,
700-nm near-infrared (NIR) fluorescence, 800-nm NIR fluorescence, and a pseudocolored merge of the three,
with red used as the pseudocolor for 700 nm and green for 800 nm. A representative image from three independent
femoral artery thrombi is shown. B, Imaging of independent platelet populations. Porcine femoral artery exposed
to FeCl3 was imaged first with 1.8  10
10 IR-786-labeled platelets (top), then 40 minutes later using 1.8  1010
MHI-114-labeled platelets (middle row). The transected surgical specimen was also imaged (bottom row). Shown
are color video, 700-nm NIR fluorescence, 800-nm NIR fluorescence, and a pseudocolored merge of the three as
described in (A). Representative images from three independent femoral artery thrombi are shown. C, Hematox-
ylin and eosin (H&E) histology and consecutive NIR fluorescence images from the surgical specimen described in
(B). Note localization of MHI-114-labeled platelets at the luminal surface of the thrombus and IR-786-labeled
platelets dispersed throughout the entire thrombus. Shown are H&E histology, 700-nm NIR fluorescence,
800-nm NIR fluorescence, and a pseudocolored merge of the three as described in (A). Red color was used for
700-nm NIR, green for 800-nm NIR, and yellow for colocalization in the merged image. A representative image
from three independent femoral artery thrombi is shown.
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Synthesis and optical properties of 700-nm plate-
let-avid NIR fluorophores. To simultaneously measure
two different platelet populations in intact blood vessels, we
synthesized a novel class of 700-nm-emitting, platelet-avid
NIR fluorophores that complemented the 800-nm fluores-
cence of the previously described platelet-labeling agent
IR-786. Four structural analogs of IR-786 and their optical
properties are shown in Fig 1, A. Their detailed chemical
synthesis will be described elsewhere (Henary, et al, man-
uscript in preparation). Peak excitation and emission of all
four NIR fluorophores were compatible with the 700-nm
channel of the FLARE imaging system.
Optimization of platelet-loading parameters.
Although all four molecules were lipophilic cations, uptake
into platelets varied markedly over time (Fig 1, B). Because
agent MHI-114 showed a significantly higher level of
uptake than other MHI dyes (P  .01; Fig 1, B), it was
chosen for subsequent studies. In terms of the incubation
time of MHI-114, the statistical assessment of 30 minutes
vs 60 minutes, 60 minutes vs 120 minutes, and 30 minutes
vs 120 minutes is shown in Fig 1, B. The uptake at 120
minutes is significantly higher than at 30minutes (P .01).
On the other hand, the uptake at 60 minutes is not signif-
icantly higher than at 30 minutes. Therefore, 120 minutes
was used for further studies. In terms of the loading con-
centration of MHI-114, the statistical assessment of 2 M
vs 4 M, 4 Mvs 8 M, and 2 Mvs 8 M is shown in Fig
1, B. This assessment shows there is no significant differ-
ence between 4 M and 8 M, which suggests that a
plateau occurs at 4 M. Therefore, 4 M of MHI-114
was used for subsequent studies. For IR-786, the label-
ing was performed with 2-M IR-786 at 30 minutes in
our previous study.9 The incubation time and loading
concentration for IR-786 was also used in the current
study.
Bioactivity and blood half-life of MHI-114-labeled
and IR-786-labeled platelets. To determine whether
NIR fluorophore-loaded platelets remained functional, we
assessed their ability to aggregate in response to agonists.
The responses of labeled platelets to either thrombin or
collagen-related protein (CRP) are shown in Fig 2, A.
Platelet aggregometry tracings from platelets labeled with
either MHI-114 or IR-786 were nearly superimposable
onto aggregometry tracings from vehicle-only (DMSO
treated) control platelets. This observation indicates that
there were no measurable differences in response to throm-
bin and CRP in these studies, although the behavior of the
SBR of MHI-114-labeled and IR-786-labeled platelets in
vivo differedmarkedly.Whereas the SBR of IR-786-labeled
platelets had a long beta-phase blood half-life that could
not be calculated accurately over the duration of the exper-
iment, the SBR of MHI-114-labeled platelets were more
short-lived, resulting in a blood half-life of 16.4  2.2
(mean SEM) minutes (n 3; Fig 2, B). The mechanism
of the SBR of MHI-labeled platelet clearance from the
bloodstream is presently not known. tMHI-114-labeled platelets and intravascular throm-
us detection. To determine whether MHI-114-labeled
latelets remained bioactive and were able to detect preex-
sting thrombi, 3.9  1010 autologous porcine platelets
ere infused concurrently with application of FeCl3 to a
emoral artery (n  3). As shown in Fig 3, A, the growing
hrombus could be visualized in the intact vessel using
00-nm fluorescence. No signal could be detected in the
00-nm channel (data not shown), suggesting that MHI-
14 could be combined with IR-786 to follow two inde-
endent platelet populations. Quantitation of thrombus
ormation revealed that MHI-114-labeled platelets could
e detected at the site within 5 minutes of FeCl3 applica-
ion, with peak fluorescence occurring at 15 minutes
Fig 3, B).
Simultaneous detection of 700-nm MHI-114-
abeled platelets and 800-nm IR-786-labeled platelets
n vitro and in vivo. Because lipophilic cations could
heoretically translocate passively among cells, we split a
latelet preparation in half and labeled each half separately
ith MHI-114 or IR-786. Then, platelets were mixed
ogether and examined microscopically at the single-plate-
et level for evidence of dye transfer. As shown in Fig 4, A,
o such transfer was detected, and no cross-contamination
f the two NIR fluorescence channels was found (ie, yellow
olor in the merged image).
A similar experiment was performed in vivo (n 1; Fig
, B), where 1.9  1010 IR-786-labeled platelets were
nfused into pigs 20 minutes before thrombus formation in
he femoral artery using FeCl3. Imaging at 700 nm and 800
m confirmed no cross-contamination. Yet, when 1.9 
010 MHI-114-labeled platelets were infused, 700-nm flu-
rescence became visible as a subset of the 800-nm fluores-
ence signal, which was more clearly visible in the surgical
pecimen (Fig 4, B). H&E staining of these vessels demon-
trated large thrombi oriented toward the portion of the
essel exposed to FeCl3 (Fig 4, C). NIR microscopy at 800
m showed that IR-786-labeled platelets were diffusely incor-
orated throughout the body of the thrombus. In contrast,
00-nm fluorescence revealed MHI-114-labeled platelets lo-
alized exclusively to the luminal rim of the thrombus. These
tudies confirmed our ability to follow two independent plate-
et populations during thrombus formation in thick-walled
essels in vivo.
Quantitation of antiplatelet drug effects using two-
avelength in vivo NIR fluorescence imaging. Because
he SBR of MHI-114-labeled and IR-786-labeled platelets
ould be quantified independently in vivo, and the former
ad a much shorter blood half-life, we designed an experi-
ental protocol (Fig 5,A) tomeasure the antiplatelet effect
f CILO and ASA on thrombus formation in vivo
n  3 for each drug). In this protocol, a single infusion of
.3  1010, long-acting, 800-nm IR-786-labeled platelets
erved as an internal control for the fluorescence intensity
f the initial thrombus induced by FeCl3 treatment of the
eft femoral artery. Then, a second population of autolo-
ous platelets was loaded with 700-nm MHI-114 and
reated with either 50-M cilostazol or 50-M aspirin
JOURNAL OF VASCULAR SURGERY
July 2012178 Ashitate et alFig 5. Quantitation of the effect of cilostazol (CILO) and aspirin (ASA) on platelet incorporation into pre-existing
thrombi. A, Protocol for femoral artery injury, drug-treated platelet infusion, blood sampling, and intraoperative
near-infrared (NIR) fluorescence imaging. B, Simultaneous 700-nm and 800-nm NIR fluorescence imaging of the
intact femoral artery as described in detail in (A) after pretreatment with 50-MCILO. Shown are color video, 700-nm
NIR fluorescence, 800-nmNIR fluorescence, and a pseudocoloredmerge of the three, with red used as the pseudocolor
for 700 nm, green for 800 nm, and yellow for colocalization in the merged image. Ex vivo surgical specimens are shown
below the dashed line. Representative images are from three independent femoral artery thrombi using CILO-treated
platelets. ASA results are not shown. C, Comparison of the signal-to-background (SBR) (700 nm/800 nm %; mean
SEM) between CILO() and CILO(-), or between ASA() and ASA(-) are shown. Shown are the P values for the
indicated statistical comparisons by a one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons
test. **  P  .01. DMSO, Dimethyl sulfoxide.
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Volume 56, Number 1 Ashitate et al 179before infusion. The fluorescence intensity of the left fem-
oral artery thrombus was measured over time, and once
blood sampling confirmed complete clearance of MHI-
114-labeled platelets from the circulation, a control throm-
bus was formed in the contralateral (right) femoral artery
using FeCl3 and measured in the same animal using MHI-
114-labeled platelets pretreated with vehicle (DMSO) only.
As shown in Fig 5, B, intraoperative imaging and
analysis of the surgical specimen revealed that CILO pre-
treatment markedly reduced the fluorescence intensity of
the growing thrombus. Quantitation of the ratio of
700-nm to 800-nm fluorescence (Fig 5, C) confirmed a
significant antiplatelet effect of CILO as compared to aspi-
rin in this large animal model system. In the setting of
CILO pretreatment, thrombus size was reduced by 51 2
(mean  SEM; n  3) percentage relative to the control
thrombus, but in the setting of aspirin was only reduced by
10  1 (mean  SEM; n  3) percentage relative to the
control thrombus.
DISCUSSION
We describe the synthesis and characterization of
700-nm platelet-avid indocyanine derivatives that incorpo-
rate at relatively high levels after simple addition to the
extracellular buffer. MHI-114 concentrated to4.1 106
molecules of fluorophore per platelet, which is similar to
the 3.5  106 molecules of fluorophore per platelet
reported previously for IR-786. As long as quenching is
avoided and bioactivity is maintained, these high levels of
fluorophore loading enable sensitive detection of thrombi
(SBR 2.5), even when only 3% of circulating platelets
are labeled.
Because the SBR of 700-nm MHI-114-labeled plate-
lets are relatively short-lived in vivo, we used this as an
advantage to study multiple thrombi formation in the same
animal (Fig 5). This short blood half-life also complements
that of 800-nm IR-786-labeled-platelets, which are more
useful for longer-duration experiments. The difference in
half-lives also permitted us to study the antiplatelet effects
of CILO and ASA on platelet accumulation in intact vessels
approaching the size of humans.
The use of NIR fluorescent platelets as molecular
probes offers new opportunities for studying thrombus
formation in animal models of myocardial infarction,
stroke, and peripheral vascular disease. They also enable
real-time intraoperative interrogation of intact vessels; for
example, intraoperative graft occlusion occurs as a compli-
cation of cardiac bypass surgery in approximately 1.5% to
5.0% of procedures.17,18 It should now be possible to use
the technology we describe to test drugs that prevent
thrombus formation, as well as to test drugs that disaggre-
gate established thrombi. MHI-114 and IR-786 could also
be used to label leukocytes, stem cells, or other cell types
thought to contribute to thrombus formation, and to
quantify the contribution of any two-cell populations to
thrombogenesis.We thank Rita G. Laurence for assistance with animal
urgery, Lindsey Gendall for editing, and Eugenia Trabuc-
hi and Keys Linda for administrative assistance.
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